Identification and Androgen Regulation of Two Proteins Released by T47D Human Breast Cancer Cells1

Total Page:16

File Type:pdf, Size:1020Kb

Identification and Androgen Regulation of Two Proteins Released by T47D Human Breast Cancer Cells1 [CANCER RESEARCH 47, 2787-2792, June 1, 1987] Identification and Androgen Regulation of Two Proteins Released by T47D Human Breast Cancer Cells1 D. Chalbos, D. Haagensen, T. Parish, and H. Rochefort2 1NSERM U148, Unitéd'Endocrinologie Cellulaire et Moléculaire,34100 Montpellier, France [D. C., H. R.]; Department of Surgery, The Jewish Hospital of St. Louis, Washington University Medical Center, St. Louis, Missouri 63110 [D. H.J; and Cambridge Research Laboratory, Cambridge, Massachusetts 02139 [T. P.] ABSTRACT scribed several glycoproteins isolated from breast gross cystic Three [35S|methionine-labeled polypeptides released by T47D human disease fluids, three of which have been identified and charac terized. They include a progesterone-binding protein (M, breast cancer cells have been identified as corresponding to two proteins 24,000), the Zn-a2-glycoprotein (M, 44,000), and a glycoprotein previously described in breast gross cystic disease fluid. A M, 43,000 protein was immunoprecipitated by polyclonal antibodies to the 7,n-«2- with a molecular weight of approximately 15,000, termed GCDFP-153 (8). These proteins have been purified to homo glycoprotein. A M, 18,000 and a M, 13,000 polypeptide were both immunoprecipitated by four monoclonal antibodies directed against four geneity, and antibodies (8-10) and cDNA (11, 12) probes for separate epitopes of M, 15,000 gross cystic disease fluid protein, a major GCDFP-15 have been prepared. protein that is characteristic of apocrine gland secretions. In sodium Specific immunoprecipitation was used here to identify two dodecyl sulfate-polyacrylamide gel electrophoresis, purified M, 15,000 proteins secreted by T47D cells as the Zn-a2-glycoprotein and gross cystic disease fluid protein migrated at the level of the M, 18,000 the GCDFP-15 protein of breast gross cystic disease fluid. The protein of T47Dcells. androgen-induced increase in the accumulation of GCDFP-15 The proteins were regulated by androgens and progestins. In addition to a general stimulation of protein secretion, 5a-dihydrotestosterone was confirmed by immunoprecipitation of cellular proteins. (DHT) specifically increased, by 2- to 20-fold, the release of the M, The regulation of these two proteins by progestin and androgen is probably mediated by the androgen receptor, based on dose- 43,000 and M, 18,000 proteins into the medium. DHT also increased the cellular level of the M, 18,000 protein, as shown by immunoprecipitation response experiments and inhibition by flutamide. with a M, 15,000 gross cystic disease fluid protein antibody, which suggests a stimulation of protein synthesis. The progestin 17,21-di- methyl-19-nor-4,9-pregnadiene-3,20-dione also increased the release in MATERIALS AND METHODS the medium of the M, 43,000 and M, 18,000 proteins, but higher molar Cell Culture. Clone 11 (passage 57) is a subline of the T47D cell line concentrations were required than in the case of DHT. The induction of (13), which was obtained by the agar method (14) in the laboratory of these proteins by DHT and 17,21-dimethyl-19nor,4,9-pregnadiene-3,20- Dr. I. Keydar (15). Single cells were grown in monolayers and recloned dione was specifically inhibited by the antiandrogen flutamide which has by the same method. Several single isogenic cell sublines were obtained, no effect on other progestin-regulated proteins. This suggests an effect including clone 11, which retains the marker chromosome of the mediated by the androgen receptor. parental line and contains high levels of progesterone receptors, as well This is the first report on the identification of two proteins induced by as estrogen, androgen, and glucocorticoid receptors (16).4 T47D clone androgens in a human breast cancer cell line. These proteins should be 11 is routinely cultured in RPMI 1640 supplemented with 10% fetal useful in studying the role of androgens in human mammary tumors and calf serum and 0.6 ¿tg/rnlbovine insulin (Sigma Chemical Co., St. their mechanism of action in cell culture. Louis, MO). The protocol used to test the effects of steroids on protein secretion INTRODUCTION has been described previously (2, 4). Briefly, cells were cultured with 10% (3 days) and then 3% (2 days) FCS-DCC to remove steroids. They Human mammary cancer cell lines have been found to con were then plated out in 0.8-cm-diameter microwells (15,000 cells/well) tain sex steroid receptors and to respond to sex steroid hor in medium plus 3% FCS-DCC. Two days later, steroids were added in mones with respect to specific protein synthesis and the control ethanol solution (final ethanol concentration, 0.2%) and solvent was of cell proliferation. Proteins induced by steroids in these in added to control cells. Flutamide was kindly donated by Schering vitro systems provide new potential markers of hormone re Laboratories (Bloomfield, NJ) and hormones were given by Roussel Uclaf (Romainville, France). The compounds were 99% pure as shown sponsiveness. These systems can also be used to study the by thin layer chromatography. After hormonal stimulation, cells were mechanisms by which steroid hormones modulate gene expres labeled for 6 h with 200 /iCi/ml [35S]methionine or [35S]cysteine (Ra- sion and cancer cell proliferation. In MCF7 cells, several estro diochemical Center, Amcrsham. England; specific activity, 600 Ci/ gen-regulated proteins have been reported (1,2). More recently, mmol) in 50 u\ of medium containing one-tenth the normal concentra progestin-regulated proteins have been found within cells (T47D tion of methionine or cysteine, respectively. For analysis of cellular or MCF7 cells) (3) or secreted by cells (T47D cells) (4). These proteins, cells were labeled for 4 h with [35S]methionine and washed proteins are defined according to their molecular weight under twice with phosphate-buffered saline. They were then dissolved in 50 ul of lysis buffer A, described by O'Farrell (17), containing 0.5% (w/v) denaturing conditions. sodium dodecyl sulfate. Cell lysis was completed by freezing and Among the progestin-regulated proteins secreted by T47D thawing 3 times (-20°C). cells, the M, 43,000, 22,000, and 18,000 proteins were also Immunoprecipitations. Radioactivity incorporated into proteins re found to be regulated by androgens (4, 5) and appear to be leased into the medium was determined by TCA precipitation of ali- related to the synandrogenic effect of progestins (6). quots of the media (5 ul); 60,000 cpm of TCA-precipitable material or Working separately, Haagensen and Mazoujian (7) have de- 'The common names and abbreviations used are: GCDFP-15, gross cystic Received1/3/86; revised10/20/86, 3/5/87; accepted3/10/87. disease fluid protein (M, 15,000); R5020 or promegestone, 17,21-dimethyl-19- The costs of publicationof this article were defrayedin part by the payment nor-4,9-pregnadiene-3,20-dione; DHT, Sa-dihydrotestosterone, 17j3-hydroxy-5o- of page charges. This article must therefore be hereby marked advertisementin androstane-3-one; RU486, 17/3-hydroxy-11¡3-(4-dimethylaminophenyl-1)-17a- accordancewith 18U.S.C. Section 1734solelyto indicatethis fact. (prop-l-ynil)estra-4,9-dien-3-one; flutamide, a,a,a-trifluoro-2-methyl-4'-nitro-m- 1This work was funded by the Institut National de la Santéetde la Recherche propionotoluidide; FCS-DCC, fetal calf serum treated with dextran-coated char Médicale,theUniversity of Montpellier I, and the Association pour la Recherche coal; SDS, sodium dodecyl sulfate; TCA, trichloroacetic acid; cDNA, comple sur le Cancer. mentary DNA. 2To whom requests for reprints should be addressed. 4 D. Chalbos and F. Vignon, unpublished experiments. 2787 Downloaded from cancerres.aacrjournals.org on October 1, 2021. © 1987 American Association for Cancer Research. ANDROGEN-INDUCED PROTEINS IN BREAST CANCER 60 ni of culture medium, as specified in the figure legends, were methionine-labeled proteins secreted by T47D cells (clone 11) incubated with antibodies for l h at 20"< in 100 HIMTris (pH 8), 100 has been reported previously (4). Cells treated for 5 days with IHMNaCl, 0.5% Nonidet P-40, 2 mM phenylmethylsulfonyl fluoride, DHT secreted more proteins than control cells, as seen by and 0.5% (w/v) bovine serum albumin (final volume, 100 (¿1).The analyzing the same volume of medium on SDS-polyacrylamide antibodies were 10 n\ of rabbit antiserum to Zn-«2-glycoprotein or nonimmune rabbit serum; 2 ¿ilofmouse monoclonal antibodies A5, gel (Fig. 1, a and b). Three polypeptides, Mr 43,000, 18,000, D6, B1, or B15, directed against GCDFP-15 (10); or 4 /¿Iofnonimmune and 13,000, accumulated more specifically, according to anal mouse IgG (1 mg/ml). Protein A-Sepharose (100 pi; 6% w/v in the ysis of the same amounts of TCA-precipitable material (Fig. 1, same buffer) was then added. Tubes were agitated for 2 h at 4°Cand c and d) which have been shown to be induced by R5020 and then centrifuged at 10,000 x g for 2 min. The protein A-Sepharose gel DHT (4). The different molecular weights of the two smaller was washed 4 times with 1.2 ml of Tris-LiCl buffer (100 mM Tris-HCl, peptides (M, 18,000 and 13,000) were obtained using more pH 8.6-500 mM LiCl-0.5% Nonidet P-40) and then once with 50 mM suitable 15% or 20% polyacrylamide gels. Tris-HCl, pH 6.8. The antigen-immunoglobulin complexes were dis In an attempt to identify these androgen-regulated polypep sociated from the protein A-Sepharose gel by heating for 10 min at 90°Cin 60 pi of electrophoretic sample buffer. Tubes were centrifuged tides, several antibodies to proteins of similar molecular weight at 10,000 x g for 2 min and the supernatant was loaded onto SDS- were tested.
Recommended publications
  • Pp375-430-Annex 1.Qxd
    ANNEX 1 CHEMICAL AND PHYSICAL DATA ON COMPOUNDS USED IN COMBINED ESTROGEN–PROGESTOGEN CONTRACEPTIVES AND HORMONAL MENOPAUSAL THERAPY Annex 1 describes the chemical and physical data, technical products, trends in produc- tion by region and uses of estrogens and progestogens in combined estrogen–progestogen contraceptives and hormonal menopausal therapy. Estrogens and progestogens are listed separately in alphabetical order. Trade names for these compounds alone and in combination are given in Annexes 2–4. Sales are listed according to the regions designated by WHO. These are: Africa: Algeria, Angola, Benin, Botswana, Burkina Faso, Burundi, Cameroon, Cape Verde, Central African Republic, Chad, Comoros, Congo, Côte d'Ivoire, Democratic Republic of the Congo, Equatorial Guinea, Eritrea, Ethiopia, Gabon, Gambia, Ghana, Guinea, Guinea-Bissau, Kenya, Lesotho, Liberia, Madagascar, Malawi, Mali, Mauritania, Mauritius, Mozambique, Namibia, Niger, Nigeria, Rwanda, Sao Tome and Principe, Senegal, Seychelles, Sierra Leone, South Africa, Swaziland, Togo, Uganda, United Republic of Tanzania, Zambia and Zimbabwe America (North): Canada, Central America (Antigua and Barbuda, Bahamas, Barbados, Belize, Costa Rica, Cuba, Dominica, El Salvador, Grenada, Guatemala, Haiti, Honduras, Jamaica, Mexico, Nicaragua, Panama, Puerto Rico, Saint Kitts and Nevis, Saint Lucia, Saint Vincent and the Grenadines, Suriname, Trinidad and Tobago), United States of America America (South): Argentina, Bolivia, Brazil, Chile, Colombia, Dominican Republic, Ecuador, Guyana, Paraguay,
    [Show full text]
  • Canine Vascular Tissues Are Targets for Androgens, Estrogens, Progestins, and Glucocorticoids
    Canine vascular tissues are targets for androgens, estrogens, progestins, and glucocorticoids. K B Horwitz, L D Horwitz J Clin Invest. 1982;69(4):750-758. https://doi.org/10.1172/JCI110513. Research Article Sex differences and steroid hormones are known to influence the vascular system as shown by the different incidence of atherosclerosis in men and premenopausal women, or by the increased risk of cardiovascular diseases in women taking birth control pills or men taking estrogens. However, the mechanisms for these effects in vascular tissues are not known. Since steroid actions in target tissues are mediated by receptors, we have looked for cytoplasmic steroid receptor proteins in vascular tissues of dogs. We find specific saturable receptors, sedimenting at 8S on sucrose density gradients for estrogens (measured with [3H]estradiol +/- unlabeled diethylstilbestrol), androgens (measured with [3H]R1881 +/- unlabeled R1881 and triamcinolone acetonide), and glucocorticoids (measured with [3H]dexamethasone +/- unlabeled dexamethasone); they are absent for progesterone (measured with [3H]R5020 +/- unlabeled R5020 and dihydrotestosterone). Progesterone receptors can, however, be induced by 1-wk treatment of dogs with physiological estradiol concentrations (100 pg/ml serum estrogen), indicating a functional estrogen receptor. Receptor levels range from 20 to 2,000 fmol/mg DNA. They are specific for each hormone; unrelated steroids fail to complete for binding. Low dissociation constants, measured by Scatchard analyses, show that binding is of high affinity. Steroid binding sites are in the media and/or adventitia since they persist when the intima is removed. Compared with the arteries, receptor levels are reduced 80% in inferior venae cavae of […] Find the latest version: https://jci.me/110513/pdf Canine Vascular Tissues Are Targets for Androgens, Estrogens, Progestins, and Glucocorticoids KATHRYN B.
    [Show full text]
  • Chlormadinone Acetate As a Possible Effective Agent for Congenital Adrenal Hyperplasia to Suppress Elevated ACTH and Antagonize Masculinization
    Endocrine Journal 1995, 42(4), 505-508 Chlormadinone Acetate as a Possible Effective Agent for Congenital Adrenal Hyperplasia to Suppress Elevated ACTH and Antagonize Masculinization YUKIo KAGEYAMA, SATOSHIKITAHARA, TETSUROTSUKAMOTO, TOsHIHIKOTSUJII, SYUITIGOTO ANDHIROYUKI OSHIMA Department of Urology, Tokyo Medical and Dental University School of Medicine, Tokyo 113, Japan Abstract. We report two cases of congenital adrenal hyperplasia (CAH) in which administration of chlormadinone acetate (CMA), a substituted progestational agent for prostatic disease, suppressed ACTH hypersecretion and lowered plasma testosterone levels. Case 1 was 83-year-old male with advanced prostatic carcinoma and CAH due to 21-hydroxylase deficiency. His plasma testosterone did not decrease in spite of a bilateral orchiectomy. Case 2 was 40-year-old female with CAH due to 21- hydroxylase deficiency suffering from virilization after the cessation of cortisol supplement therapy because of her breast carcinoma. In these two cases, 'ral administration of CMA at a daily dose of 75- 100 mg suppressed ACTH and cortisol to subnormal levels and reduced testosterone levels. With the suppressive effect on ACTH excess and antiandrogenic action, CMA may be suitable for patients with CAH suffering from symptoms due to overproduced ACTH or adrenal androgen. Key words: Chlormadinone acetate , Congenital adrenal hyperplasia, ACTH suppression (Endocrine Journal 42: 505-508,1995) CHLORMADINONE acetate (17u-acetoxy-6-chlo- adrenal hyperplasia (CAH). Chlormadinone ace- ro-4,6-pregnadiene-3,20-dione; CMA), a substituted tate, administered for the prostatic carcinoma, progestational agent, has been used in the treat- suppressed hypersecretion of ACTH and lowered ment of benign prostatic hyperplasia (BPH) and plasma testosterone levels. With this experience prostatic carcinoma because of its anti-androgenic in mind, we administered CMA to a female pa- properties.
    [Show full text]
  • Combined Estrogen–Progestogen Menopausal Therapy
    COMBINED ESTROGEN–PROGESTOGEN MENOPAUSAL THERAPY Combined estrogen–progestogen menopausal therapy was considered by previous IARC Working Groups in 1998 and 2005 (IARC, 1999, 2007). Since that time, new data have become available, these have been incorporated into the Monograph, and taken into consideration in the present evaluation. 1. Exposure Data 1.1.2 Progestogens (a) Chlormadinone acetate Combined estrogen–progestogen meno- Chem. Abstr. Serv. Reg. No.: 302-22-7 pausal therapy involves the co-administration Chem. Abstr. Name: 17-(Acetyloxy)-6-chlo- of an estrogen and a progestogen to peri- or ropregna-4,6-diene-3,20-dione menopausal women. The use of estrogens with IUPAC Systematic Name: 6-Chloro-17-hy- progestogens has been recommended to prevent droxypregna-4,6-diene-3,20-dione, acetate the estrogen-associated risk of endometrial Synonyms: 17α-Acetoxy-6-chloro-4,6- cancer. Evidence from the Women’s Health pregnadiene-3,20-dione; 6-chloro-Δ6-17- Initiative (WHI) of adverse effects from the use acetoxyprogesterone; 6-chloro-Δ6-[17α] of a continuous combined estrogen–progestogen acetoxyprogesterone has affected prescribing. Patterns of exposure Structural and molecular formulae, and relative are also changing rapidly as the use of hormonal molecular mass therapy declines, the indications are restricted, O CH and the duration of the therapy is reduced (IARC, 3 C 2007). CH3 CH3 O C 1.1 Identification of the agents CH3 H O 1.1.1 Estrogens HH For Estrogens, see the Monograph on O Estrogen-only Menopausal Therapy in this Cl volume. C23H29ClO4 Relative molecular mass: 404.9 249 IARC MONOGRAPHS – 100A (b) Cyproterone acetate Structural and molecular formulae, and relative Chem.
    [Show full text]
  • Subject Index
    Subject Index absorption enhancer 166 bile acid Ill; 160 (see also permeability enhancer) binary complexes 74 acetaminophen 61, 128, 138, 143,214 bioavailability 105, 108, 145, 153, 156, 166, (see also paracetamol) 169,173,174,177,181-183 acetic acid 75 biopharmaceutics 105 acetohexaminde 119 biphenyl 73 acetone 74, 85 biphenyl acetate 169, 175, 176,208 acetylsalicylic acid 65, 66, 95,154,200 biphenyl acetic acid 169, 121 acid hydrolysis 12 biphenylacetic ester 200 adenosinediphosphate 123 bisabolol 66 adhesive tapes 187,211,212 bitter taste 127 adiabatic compressibility 6 (see also taste, unpleasant) aerosols 188 branched CDs 3, 44,157 alfaxalone 162 brexin 218 Allidex 218 bromo-benzene 48, 73 amantadine 54 buccal absorption 155 amino acids 134 buserelin acetate 183, 193,203 amorphous state 146 butylparaben 171 Amphotericin B 13,61,66 amylase 33 caboxymethylethyl-~CO 192 androsterone 42 caffeine 128 anethol129 camomile oil 89, 103, 130,213 aniline 53, 73, 74 camphor 129, 174, 186,209,213 anthracene 73 canrenone 68, 108 aroma 129 caproic acid 73 ascaridol 66, 76 capsules 155, 197,214 ascorbic acid 128,78 caraway oil 95 aspartame 128, 155 carbamazepine 119, 161 association constant 56 carbenicillin 66 atorpine 65 carbon dioxide 85 azulenol213 carmufor 66, 79, 114, 175, 192 Carthamus tinctorius 133 bandages 187,212 carvone68 barbiturate 34,117,124 catalytic effects 152 bead polymers 188 cataplasms 187,212 beclomethasone 119, 168 COPS 22, 41 bencyclane 128 COPS! 22,41 benexate 117 cephaeline 66, 70,157,202 benoxaprofen 69,123 cetylpyridinium
    [Show full text]
  • Effects of Anti-Androgen, Tzp-4238 and Chlormadinone Acetate on the Adrenal Cortex -Histo- Pathological and Immunocyto- Chemical Studies
    ACTA HISTOCHEM. CYTOCHEM. Vol. 27, No. 4, pp. 365-372, 1994 EFFECTS OF ANTI-ANDROGEN, TZP-4238 AND CHLORMADINONE ACETATE ON THE ADRENAL CORTEX -HISTO- PATHOLOGICAL AND IMMUNOCYTO- CHEMICAL STUDIES- MASANORI MURAKOSHI, RIE INADA, MASASHI TAGAWA, KAZUHIRO IIZUKA, SHUUJI MASUDA, MINORU SUZUKI, ATSUSHI MIZOKAMI* AND KEIICHI WATANABE ** Safety Research Department, Teikoku Hormone Mfg. Co. Ltd., 1604 Shimosakunobe, Takatsu-ku, Kawasaki 213, *Department of Molecular Cell Biology, University of Occupational and Environmental Health, Kitakyushu 806 and **Department of Pathology, Tokai University School of Medicine, Bohseidai, Isehara-city, Kanagawa 259-11 Received for publication May 12, 1994, in revised form July 22, 1994 and re-revised form August 24, 1994 The atrophic effects of two synthetic steroidal anti-androgens, chlormadinone acetate (CMA) and TZP-4238, on the adrenal gland of rats were investigated by histopathological and immunocytochemical procedures. Male Sprague-Dawley rats were divided into four experimental groups. Group 1 consisted of intact controls. Groups 2 and 3 received TZP-423810 mg/kg/day and CMA 50 mg/kg/day p.o., respective- ly, for 3 weeks. Group 4 received distilled water containing 2% Tween 80 instead of TZP-4238 or CMA. CMA caused marked atrophy of the adrenal gland. Histopathologically, the remarkable atrophy was observed in the adrenal cortical cells of zonae fasciculata and reticularis. Intracellular localization of glutathione-peroxidase (GSH-PO) which effectively reduces the lipid peroxides, was mainly observed in the cytoplasmic matrix (cytosol GSH-PO) near the mitochondria or lipid droplets. In ddition, immunoreactivi- ty of intramitochondrial GSH-PO (mitochondrial GSH-PO) was less than that in the controls.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2008/0161324 A1 Johansen Et Al
    US 2008O161324A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2008/0161324 A1 Johansen et al. (43) Pub. Date: Jul. 3, 2008 (54) COMPOSITIONS AND METHODS FOR Publication Classification TREATMENT OF VRAL DISEASES (51) Int. Cl. (76) Inventors: Lisa M. Johansen, Belmont, MA A63/495 (2006.01) (US); Christopher M. Owens, A63L/35 (2006.01) Cambridge, MA (US); Christina CI2O I/68 (2006.01) Mawhinney, Jamaica Plain, MA A63L/404 (2006.01) (US); Todd W. Chappell, Boston, A63L/35 (2006.01) MA (US); Alexander T. Brown, A63/4965 (2006.01) Watertown, MA (US); Michael G. A6II 3L/21 (2006.01) Frank, Boston, MA (US); Ralf A6IP3L/20 (2006.01) Altmeyer, Singapore (SG) (52) U.S. Cl. ........ 514/255.03: 514/647; 435/6: 514/415; Correspondence Address: 514/460, 514/275: 514/529 CLARK & ELBNG LLP 101 FEDERAL STREET BOSTON, MA 02110 (57) ABSTRACT (21) Appl. No.: 11/900,893 The present invention features compositions, methods, and kits useful in the treatment of viral diseases. In certain (22) Filed: Sep. 13, 2007 embodiments, the viral disease is caused by a single stranded RNA virus, a flaviviridae virus, or a hepatic virus. In particu Related U.S. Application Data lar embodiments, the viral disease is viral hepatitis (e.g., (60) Provisional application No. 60/844,463, filed on Sep. hepatitis A, hepatitis B, hepatitis C, hepatitis D, hepatitis E). 14, 2006, provisional application No. 60/874.061, Also featured are screening methods for identification of filed on Dec. 11, 2006. novel compounds that may be used to treat a viral disease.
    [Show full text]
  • Chlormadinone Acetate
    Chlormadinone Acetate sc-211070 Material Safety Data Sheet Hazard Alert Code EXTREME HIGH MODERATE LOW Key: Section 1 - CHEMICAL PRODUCT AND COMPANY IDENTIFICATION PRODUCT NAME Chlormadinone Acetate STATEMENT OF HAZARDOUS NATURE CONSIDERED A HAZARDOUS SUBSTANCE ACCORDING TO OSHA 29 CFR 1910.1200. NFPA FLAMMABILITY1 HEALTH0 HAZARD INSTABILITY0 SUPPLIER Santa Cruz Biotechnology, Inc. 2145 Delaware Avenue Santa Cruz, California 95060 800.457.3801 or 831.457.3800 EMERGENCY ChemWatch Within the US & Canada: 877-715-9305 Outside the US & Canada: +800 2436 2255 (1-800-CHEMCALL) or call +613 9573 3112 SYNONYMS C23-H29-Cl-O4, 17-acetoxy-6-chloro-6-dehydroprogesterone, 17alpha-acetoxy-6-chloro-6-dehydroprogesterone, "17alpha-acetoxy-6-chloro-6, 7-dehydroprogesterone", "17alpha-acetoxy-6-chloro-4, 6-pregnadiene-3, 20-dione", "17alpha-acetoxy-6-chloropregna-4, 6-diene-3, 20-dione", "17-(acetyloxy)-6-chloropregna-4, 6-diene-3, 20-dione", "6-chloro-17alpha-acetoxy-4, 6-pregnadiene-3, 20-dione", "delta(sup 6)-6-chloro-17alpha-acetoxyprogesterone", "6-chloro-delta(sup 6)-17-acetoxyprogesterone", "6-chloro-delta(sup 6)-(17alpha)acetoxyprogesterone", "6-chloro- delta(sup 6)-dehydro-17-acetoxyprogesterone", 6-chloro-6-dehydro-17alpha-acetoxyprogesterone, "6-chloro- 6-dehydro-17-alpha-hydroxyprogesterone acetate", "6-chloro-17-alpha-hydroxypregna-4, 6-diene-3, 20-dione acetate", "6-chloro-17-alpha-hydroxy-delta(sup 6)-progesterone acetate", "6-chloro-delta(sup 4, 6)-pregnadiene- 17-alpha-ol-3, 20-dione-17-", acetate, "6-chloro-pregna-4, 6-dien-17-alpha-ol-3,
    [Show full text]
  • Customs Tariff - Schedule Xxi - 1
    CUSTOMS TARIFF - SCHEDULE XXI - 1 Section XXI WORKS OF ART, COLLECTORS' PIECES AND ANTIQUES Issued January 1, 2013 CUSTOMS TARIFF - SCHEDULE 99 - i Chapter 99 SPECIAL CLASSIFICATION PROVISIONS - COMMERCIAL Notes. 1. The provisions of this Chapter are not subject to the rule of specificity in General Interpretative Rule 3 (a). 2. Goods which may be classified under the provisions of Chapter 99, if also eligible for classification under the provisions of Chapter 98, shall be classified in Chapter 98. 3. Goods may be classified under a tariff item in this Chapter and be entitled to the Most-Favoured-Nation Tariff or a preferential tariff rate of customs duty under this Chapter that applies to those goods according to the tariff treatment applicable to their country of origin only after classification under a tariff item in Chapters 1 to 97 has been determined and the conditions of any Chapter 99 provision and any applicable regulations or orders in relation thereto have been met. 4. The words and expressions used in this Chapter have the same meaning as in Chapters 1 to 97. Issued January 1, 2013 99 - 1 CUSTOMS TARIFF - SCHEDULE Tariff Unit of MFN Applicable SS Description of Goods Item Meas. Tariff Preferential Tariffs 9901.00.00 Articles and materials for use in the manufacture or repair of the Free CCCT, LDCT, GPT, UST, following to be employed in commercial fishing or the commercial MT, MUST, CIAT, CT, harvesting of marine plants: CRT, IT, NT, SLT, PT, COLT, JT: Free Artificial bait; Carapace measures; Cordage, fishing lines (including marlines), rope and twine, of a circumference not exceeding 38 mm; Devices for keeping nets open; Fish hooks; Fishing nets and netting; Jiggers; Line floats; Lobster traps; Lures; Marker buoys of any material excluding wood; Net floats; Scallop drag nets; Spat collectors and collector holders; Swivels.
    [Show full text]
  • Crystallographic and Spectroscopic Study on a Known Orally Active Progestin
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by AIR Universita degli studi di Milano Accepted Manuscript Crystallographic and spectroscopic study on a known orally active progestin Patrizia Ferraboschi, Pierangela Ciuffreda, Samuele Ciceri, Paride Grisenti, Carlo Castellano, Fiorella Meneghetti PII: S0039-128X(15)00246-9 DOI: http://dx.doi.org/10.1016/j.steroids.2015.09.007 Reference: STE 7841 To appear in: Steroids Received Date: 24 April 2015 Revised Date: 10 August 2015 Accepted Date: 27 September 2015 Please cite this article as: Ferraboschi, P., Ciuffreda, P., Ciceri, S., Grisenti, P., Castellano, C., Meneghetti, F., Crystallographic and spectroscopic study on a known orally active progestin, Steroids (2015), doi: http://dx.doi.org/ 10.1016/j.steroids.2015.09.007 This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. Crystallographic and spectroscopic study on a known orally active progestin Patrizia Ferraboschi,a,* Pierangela Ciuffreda,b Samuele Ciceri,a Paride Grisenti,c Carlo Castellano,d and Fiorella Meneghettie aDipartimento di Biotecnologie Mediche e Medicina Traslazionale, Università degli Studi di Milano, Via Saldini 50, 20133 Milano, Italy bDipartimento di Scienze Biomediche e Cliniche “Luigi Sacco”, Università degli Studi di Milano, Via G.B.
    [Show full text]
  • Action of a Novel Nonsteroidal Antiandrogen, AA560 KEIZO
    Endocrinol. Japon. 1980, 27 (1), 69-76 Action of a Novel Nonsteroidal Antiandrogen, AA560 KEIZO SHIDA1, HIDETOSHI YAMANAKA1, ATSUSHI KOYA1, KATSUMIWAKABAYASHI2, HIROSHIMORI3, KENYU SHIBATA3 ANDEIICHIRO SHIMAZAWA3 1D epartment of Urology School of Medicine, Gunma University, Maebashi, 'Hormone Assay Center, Institute of Endocrinology, Gunma University, Maebashi, 3Research Division, Teikoku Hormone Mfg. Co., Kawasaki Synopsis The antiandrogenic properties of a new nonsteroidal antiandrogens, AA560 (N- (2-chloromethyl-2-hydroxypropionyl)-3, 4, 5-trichloroaniline) were investigated. The ventral prostate, dorselateral prostate and coagulating gland weights in rats given AA560 at1-9mg/head were significantly less than those in the intact rats. The seminal vesicle weights in rats given3-9mg/head were significantly less than those of the intact group. In intact animals given daily3or9mg of AA560there were significantly increases of serum FSH, LH and testosterone concentrations. In the in vivo experiment, the pretreatment with AA560decreased the uptake of 3H-androgens in the nuclear fraction of the ventral prostate. On the other hand, a significant increase in the uptake of3H-radioactivity in the cytosol fraction was observed. It was proved by the in vitro displacement study that AA560inhibited the binding of5a-dihydrotestosterone with a receptor protein in the prostatic cytosol. An intensive effort has been directed the transfer of5a-DHT into nucleus (Belham toward the research of antiandrogens because and Neal, 1971; Mangan and Mainwaring, of usefulness of these druge in a variety of 1972). On the other hand, SK&F7690was endocrinological disorders including hirsu- reported to inhibit the cytosol receptor bin- tism, acne, male pattern baldness, benign ding to5a-DHT and the rate of 5a-DHT prostatic hypertrophy and prostatic cancer.
    [Show full text]
  • Progestins and Rat Liver : an in Vitro Study of Binding Patricia Church Brown Yale University
    Yale University EliScholar – A Digital Platform for Scholarly Publishing at Yale Yale Medicine Thesis Digital Library School of Medicine 1980 Progestins and rat liver : an in vitro study of binding Patricia Church Brown Yale University Follow this and additional works at: http://elischolar.library.yale.edu/ymtdl Recommended Citation Brown, Patricia Church, "Progestins and rat liver : an in vitro study of binding" (1980). Yale Medicine Thesis Digital Library. 2425. http://elischolar.library.yale.edu/ymtdl/2425 This Open Access Thesis is brought to you for free and open access by the School of Medicine at EliScholar – A Digital Platform for Scholarly Publishing at Yale. It has been accepted for inclusion in Yale Medicine Thesis Digital Library by an authorized administrator of EliScholar – A Digital Platform for Scholarly Publishing at Yale. For more information, please contact [email protected]. YALE MEDICAL LIBRARY 3 9002 08627 9206 J Digitized by the Internet Archive in 2017 with funding from The National Endowment for the Humanities and the Arcadia Fund https://archive.org/details/progestinsratlivOObrow PROGESTINS AND RAT LIVER: An In Vitro Study of Binding Patricia Church Brown A Thesis Submitted to the Yale University School of Medicine in Partial Fulfillment of the Requirements for the Degree of Doctor of Medicine 1980 \\od- Lib ACKNOWLEDGEMENTS I would like to acknowledge my gratitude to the following individuals: Dr. Arnold J. Eisenfeld for his patience and constructive guidance during the preparation of this thesis. This project has introduced me to some of the methods of thought of investigative science, an introduction that should be of benefit in my future career.
    [Show full text]